The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Jonah Feldman is an assistant editor for Targeted Oncology and Peers and Perspectives in Oncology. He focuses on various aspects of medicine and healthcare, including oncology, hematology, immunotherapy, and patient care, while also exploring themes such as healthcare technology and digital health. Jonah's work has been featured in prominent publications including Urology Times, Oncology Nursing News, OncLive, and CURE Media Group.